Corcept Therapeutics price target raised to $80 from $45 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Corcept Therapeutics (CORT) to $80 from $45 and keeps a Buy rating on the shares. The firm now projects Korlym sales to increase to nearly $531M in 2030 compared to its prior expectations of $338M. The firm expects Corcept’s Cushing’s syndrome franchise to remain strong in the long term.